Hara N, Ichinose Y, Motohiro A, Noge S, Miyake J, Ohta M, Hata K
Gan To Kagaku Ryoho. 1986 Jan;13(1):80-5.
From January, 1982 to March, 1983, patients with small cell carcinoma of the lung were treated at Kyushu Cancer Center. Eleven patients received combination chemotherapy-radiotherapy and one patient chemotherapy alone. The chemotherapy regimen consisted of cyclophosphamide, adriamycin and vincristine which was repeated every 4 weeks for as long as possible. Radiotherapy was administered to the primary lesion and mediastinum following 2 cycles of induction chemotherapy. The overall response rate after receiving 2 cycles of chemotherapy was 75% with 4 complete (33%) and 5 partial responses (42%). After radiotherapy, response increased to 100% with 8 complete (73%) and 3 partial responses (27%). Complete response occurred in 6 of the 7 patients with limited disease and 2 of the 5 patients with extensive disease. Overall survival rate was 73% at 1 year, 36% at 2 years and 12% at 3 years with a median survival time of 21 months. Survival was better in patients with limited disease than in those with extensive disease (median survival time, 21.5 months vs. 14 months). In the 3-Year follow-up period, all patients had recurrences consisting of 4 distant, 2 local and 5 both. Myelosuppression was mild to moderate and there were no deaths related to the side effects of treatment.
1982年1月至1983年3月期间，九州癌症中心对肺癌小细胞癌患者进行了治疗。11例患者接受了化疗联合放疗，1例患者仅接受了化疗。化疗方案包括环磷酰胺、阿霉素和长春新碱，每4周重复一次，尽可能长时间使用。诱导化疗2个周期后，对原发灶和纵隔进行放疗。接受2个周期化疗后的总体缓解率为75%，其中完全缓解4例（33%），部分缓解5例（42%）。放疗后，缓解率升至100%，其中完全缓解8例（73%），部分缓解3例（27%）。7例局限性疾病患者中有6例、5例广泛性疾病患者中有2例出现完全缓解。1年总生存率为73%，2年为36%，3年为12%，中位生存时间为21个月。局限性疾病患者的生存率优于广泛性疾病患者（中位生存时间分别为21.5个月和14个月）。在3年的随访期内，所有患者均出现复发，其中远处复发4例，局部复发2例，远处和局部均复发5例。骨髓抑制为轻至中度，无治疗副作用相关死亡。
